Regeneron Pharmaceuticals, Inc. (REGN) Chairman P Roy Vagelos Sells 1,305 Shares
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Chairman P Roy Vagelos sold 1,305 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $470.00, for a total value of $613,350.00. Following the completion of the sale, the chairman now owns 329,543 shares in the company, valued at approximately $154,885,210. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
P Roy Vagelos also recently made the following trade(s):
- On Wednesday, August 16th, P Roy Vagelos sold 10,986 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $470.17, for a total value of $5,165,287.62.
- On Friday, August 18th, P Roy Vagelos sold 15,191 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $470.15, for a total value of $7,142,048.65.
- On Thursday, May 25th, P Roy Vagelos sold 9,295 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 0.85% during mid-day trading on Friday, hitting $467.98. The company’s stock had a trading volume of 549,722 shares. The company has a market cap of $49.62 billion, a PE ratio of 46.95 and a beta of 1.66. The stock has a 50-day moving average of $490.71 and a 200-day moving average of $430.04. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the previous year, the firm posted $2.82 earnings per share. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/18/regeneron-pharmaceuticals-inc-regn-chairman-p-roy-vagelos-sells-1305-shares.html.
A number of equities research analysts recently commented on the company. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Wednesday. They issued an “outperform” rating and a $605.00 target price on the stock. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Leerink Swann reiterated a “positive” rating and issued a $552.00 target price (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Monday. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price on the stock in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $495.59.
Several institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank boosted its position in Regeneron Pharmaceuticals by 25.8% in the second quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after buying an additional 5,295 shares during the period. WINTON GROUP Ltd bought a new position in Regeneron Pharmaceuticals during the second quarter worth $713,000. Public Employees Retirement System of Ohio boosted its position in Regeneron Pharmaceuticals by 1.6% in the second quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after buying an additional 867 shares during the period. Verition Fund Management LLC boosted its position in Regeneron Pharmaceuticals by 142.7% in the second quarter. Verition Fund Management LLC now owns 1,915 shares of the biopharmaceutical company’s stock worth $941,000 after buying an additional 1,126 shares during the period. Finally, National Asset Management Inc. boosted its position in Regeneron Pharmaceuticals by 3.1% in the second quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 26 shares during the period. 67.16% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.